Intensive Care Medicine

, Volume 31, Issue 8, pp 1058–1065

Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study

  • Rosa Reina
  • Elisa Estenssoro
  • Gabriela Sáenz
  • Héctor S. Canales
  • Romina Gonzalvo
  • Gabriela Vidal
  • Gustavo Martins
  • Andrea Das Neves
  • Oscar Santander
  • Carlos Ramos
Original

Abstract

Objective

To assess renal dysfunction and outcome in patients treated exclusively with colistin vs. other antibiotics.

Design and setting

Prospective cohort study in a mixed ICU in a university-affiliated hospital.

Patients

185 patients infected with Acinetobacter baumannii and Pseudomonas aeruginosa after an ICU stay longer than 48 h: 55 in the colistin group and 130 in the noncolistin group, similar in age, APACHE II, medical status, and SOFA score.

Measurements and results

We recorded data on epidemiology and severity of illness, site of infection, renal function before and after treatment, clinical cure, and mortality. Clinical cure was defined as simultaneous normalization of central temperature (≤38°), leukocyte count (≤10,000/mm3), and PaO2/FIO2 ratio (>187). Before treatment creatinine was 0.9±0.2 in the colistin group and 0.9±0.1 in the noncolistin group; after treatment the value was 1.0±0.3 in both groups. The most frequent infection was ventilator-associated pneumonia: 53% vs. 66% in colistin and noncolistin groups, respectively, Acinetobacter was the cause in 65% and 60% and Pseudomonas in 35% and 53%. In the noncolistin group 81% of patients were treated with carbapenems. Inadequate empirical antimicrobial treatment was more frequent in the colistin group (100% vs. 8%), but there were no differences in the frequency of clinical cure on day 6 of treatment (15% and 17%) or in mortality (29% and 24%).

Conclusions

Colistin appears to be as safe and as effective as other antimicrobials for treatment of sepsis caused by Acinetobacter and Pseudomonas in critically ill patients.

Keywords

Colistin Renal failure Pseudomonas Acinetobacter ICU-acquired infections 

References

  1. 1.
    National Nosocomial Infections Surveillance System (1996) National nosocomial infections surveillance report, data summary from October 1986–April 1996. Am J Infect Control 24:380–388CrossRefPubMedGoogle Scholar
  2. 2.
    Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157:531–539PubMedGoogle Scholar
  3. 3.
    Leibovici L, Shraga I, Drucker M, Konigeberger H, Samra Z, Pitlik SD (1998) The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 244:379–386CrossRefPubMedGoogle Scholar
  4. 4.
    Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474CrossRefPubMedGoogle Scholar
  5. 5.
    Catchpole CR, Andrews JM, Brenwald N, Wise R (1997) A reassessment of the in vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 39:255–260CrossRefPubMedGoogle Scholar
  6. 6.
    Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EAG, Manrique EI, Costa SF (1999) Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumanii. Clin Infect Dis 28:1008–1011Google Scholar
  7. 7.
    Evans ME, Feola DJ, Rapp RP (1999) Polymixyn B sulfate and colistin: old antibiotics for emerging multirresistant gram-negative bacteria. Ann Pharmacother 33:960–967CrossRefPubMedGoogle Scholar
  8. 8.
    Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez J, Barrero-Almodóvar E, García-Garmendia JL, Bernabeu-Witell M, Gallego-Lara SL, Madrazo-Osuna J (2003) Treatment of multidrug-resistant Acinetobacter baumanii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with Imipenem-susceptible VAP. Clin Infect Dis 36:1111–1118CrossRefPubMedGoogle Scholar
  9. 9.
    Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L (2003) Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7:R78–R83CrossRefPubMedGoogle Scholar
  10. 10.
    Horton J, Pankey GA (1982) Polymyxin B, colistin, and sodium colistimethate. Med Clin North Am 66:135–142PubMedGoogle Scholar
  11. 11.
    Kunin CM, Bugg A (1971) Binding of polimyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis 124:394–400PubMedGoogle Scholar
  12. 12.
    Gales AC, Reis AO, Jones RN (2001) Contemporary assessment of antimicrobial susceptibility testing methods for polimixin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39:183–190CrossRefPubMedGoogle Scholar
  13. 13.
    Koch-Weser J, Sidel VW, Federman EB (1970) Adverse effects of sodium colisimethate: manifestations and specific rates during 317 courses of therapy. Ann Intern Med 72:857–868PubMedGoogle Scholar
  14. 14.
    Wolinsky E, Hines JD (1972) Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N Engl J Med 266:759–762Google Scholar
  15. 15.
    Reina R, Estenssoro E, Saenz G, Canales H, Gonzalvo R, Vidal G, Martins G, DasNeves A, Santander O, Ramos C (2004) Safety of IV colistin use in severe ICU infections. Am J Respir Crit Care Med 169:A127Google Scholar
  16. 16.
    Troché G, Moine P (1997) Is the duration of mechanical ventilation predictable? Chest 112:745–751PubMedGoogle Scholar
  17. 17.
    McCabe WR, Jackson GG (1962) Gram-negative bacteriemia. I. Etiology and ecology. Arch Intern Med 110:845–847Google Scholar
  18. 18.
    Vincent JL, De Mendoça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S (1998) Use of the SOFA score to assess the incidence of organ disfunction/failure in intensive care unit: results of a multicentre, prospective study. Crit Care Med 26:1793–1800Google Scholar
  19. 19.
    Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections (1996) In: Olmsted RN (ed) Infection control and applied epidemiology: principles and practice. Mosby, St. Louis, pp A1–A20Google Scholar
  20. 20.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis, multiple organ failure, guidelines for the use of innovative therapies in sepsis. Chest 101:1644–1655PubMedGoogle Scholar
  21. 21.
    Kollef MH, Silver P, Murphy D, Trovillion E (1995) The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 108:1655–1662PubMedGoogle Scholar
  22. 22.
    Meduri GU, Chastre J (1992) The standardization of bronchoscopic techniques for ventilator-associated pneumonia. Chest 102:557S-564SPubMedGoogle Scholar
  23. 23.
    Kollef MH, Bock KR, Richards RD, Hearns ML (1995) The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia. Ann Intern Med 122:743–748PubMedGoogle Scholar
  24. 24.
    Torres A, el-Ebiary M, Padro L, González J, de la Bellacasa JP, Ramírez J, Xaubet A, Ferrer M, Rodríguez-Roisin R (1994) Validation of different techniques for the diagnosis of ventilator-associated pneumonia: comparison with immediate postmortem pulmonary biopsy. Am J Respir Crit Care Med 149:324–331PubMedGoogle Scholar
  25. 25.
    Crouch BS, Wunderink RG, Jones CB, Leeper KV Jr (1996) Ventilator-associated pneumonia due to Pseudomona aeruginosa Chest 109:1119–1120Google Scholar
  26. 26.
    Mermel LA, Farr BM, Sheretz RJ, Raad II, O’Grady N, Harris JS, Craven DE (2001) Guidelines for the management of intravascular catheter-related infections Clin Infect Dis 32:1249–1272Google Scholar
  27. 27.
    Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS, Swartz MN (1993) Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 328:21–28CrossRefPubMedGoogle Scholar
  28. 28.
    Gantzs NM, Tkatch LS (1999) Nosocomial central nervous system infections. In: Mayhall CG (ed) Hospital epidemiology and infection control. Lippincott Williams & Wilkins, Philadelphia, pp 301–322Google Scholar
  29. 29.
    Hasbun R, Abrahamas J, Jekel J, Quagliarello VJ (2001) Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 345:1727–1733CrossRefPubMedGoogle Scholar
  30. 30.
    Brun Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 274:968–974CrossRefPubMedGoogle Scholar
  31. 31.
    Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ (2001) Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 163:1371–1375PubMedGoogle Scholar
  32. 32.
    Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, Similowski T, Mercat A, Diehl JL, Sollet JP, Tenaillon A (2000) Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 132:621–630PubMedGoogle Scholar
  33. 33.
    Rello J, Mariscal D, March F, Jubert P, Sanchez G, Valles J, Coll P (1998) Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients relapse or reinfection? Am J Respir Crit Care Med 157:912–916PubMedGoogle Scholar
  34. 34.
    Liano F, Pascual J (1996) Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int 50:811–818PubMedGoogle Scholar
  35. 35.
    Monarch Pharmaceuticals (2001) Coly-mycin M parenteral (package insert). Monarch Pharmaceuticals, BristolGoogle Scholar
  36. 36.
    Vincent JL, Bihari DJ, Suter PM, Bruining HA, Nicholas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274:639–644CrossRefPubMedGoogle Scholar
  37. 37.
    Richards MJ, Edwards JR, Culver DH et al. (1999) Nosocomial Infections in medical intensive care in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27:887–892CrossRefPubMedGoogle Scholar
  38. 38.
    Quinn JP: Clinical problems posed by multiresistant nonfermenting gram-negative pathogens (1998) Clin Infect Dis 27 [Suppl 1]:S117–S124Google Scholar
  39. 39.
    Appleman MD, Belzberg H, Citron DM, Heseltine PN, Yellin AE, Murray J, Berne TV (2000) In vitro activities of nontraditional antimicrobials against multirresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother 44:1035–1040CrossRefPubMedGoogle Scholar
  40. 40.
    Li J, Turnidge J, Milne R, Nation RL, Coulthard K (2001) In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 45:781–785CrossRefPubMedGoogle Scholar
  41. 41.
    Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC (1999) Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111:676–685Google Scholar
  42. 42.
    Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474CrossRefPubMedGoogle Scholar
  43. 43.
    Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146–155CrossRefPubMedGoogle Scholar
  44. 44.
    Clec’h C, Timsit JF, De Lassence A, Azoulay E, Alberti C, Garrouste Orgeas M, Mourvilier B, Troche G, Tafflet M, Tuil O, Cohen Y (2004) Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence on disease severity. Intensive Care Med 30:1327–1333PubMedGoogle Scholar
  45. 45.
    Kalb TH, Lorin S (2002) Infection in the chronically critically ill: unique risk profile in a newly defined population. Crit Care Clin 18:529–552CrossRefPubMedGoogle Scholar
  46. 46.
    Hughes M, McKirdy FN, Norrie J, Grant IS (2001) Outcomes of long-stay intensive care patients. Intensive Care Med 27:779–782CrossRefPubMedGoogle Scholar
  47. 47.
    Estenssoro E, González F, Laffaire E, Canales H, Sáenz G, Reina R, Dubin A (2005) Shock on admission day is the best predictor of prolonged mechanical ventilation in the ICU. Chest 127:598–603CrossRefPubMedGoogle Scholar
  48. 48.
    Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW (2003) Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37:745–751CrossRefPubMedGoogle Scholar
  49. 49.
    Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR (1989) Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 87:540–546PubMedGoogle Scholar
  50. 50.
    Garnacho J, Sole-Violan J, Sa-Borges M, Díaz E, Rello J (2003) Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: A matched cohort study. Crit Care Med 31:2478–2482CrossRefPubMedGoogle Scholar
  51. 51.
    Montero A, Corbella X, Ariza J (2003) Clinical relevance of Acinetobacter baumannii ventilator-associated pneumonia. Crit Care Med 31:257–259Google Scholar
  52. 52.
    Blot S, Vandewoude K, Colardyn F (2003) Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 29:471–475PubMedGoogle Scholar
  53. 53.
    Rello J, Díaz E (2003) Acinetobacter baumannii: a threat for the ICU? Intensive Care Med 29:350–351PubMedGoogle Scholar
  54. 54.
    Reed MD, Stern RC, O’Riordan MA, Blumer JL (2001) The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 41:645–654CrossRefPubMedGoogle Scholar
  55. 55.
    Montravers P, Fagon JY, Chastre J, Lesco M, Dombret MC, Trouillet JL, Gibert C (1993) Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 147:38–44PubMedGoogle Scholar
  56. 56.
    Ioanas M, Ewig S, Torres A (2003) Treatment failures in patients with ventilator-associated pneumonia. Infect Dis Clin North Am 17:753–771CrossRefPubMedGoogle Scholar
  57. 57.
    Browner RS, Newman TB, Cummings SR, Hulley SB (2001) Estimating sample size and power: the nitty-gritty. In: Hulley S, Cummings SR, Browner RS, Grady D, Hearst N, Newman TB (eds) Designing clinical research. An epidemiological approach, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 65–91Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Rosa Reina
    • 1
  • Elisa Estenssoro
    • 1
  • Gabriela Sáenz
    • 1
  • Héctor S. Canales
    • 1
  • Romina Gonzalvo
    • 1
  • Gabriela Vidal
    • 1
  • Gustavo Martins
    • 1
  • Andrea Das Neves
    • 1
  • Oscar Santander
    • 1
  • Carlos Ramos
    • 1
  1. 1.Intensive Care UnitHospital Interzonal de Agudos General San MartínLa PlataArgentina

Personalised recommendations